Takanori Suzuki, Kentaro Matsuura, Yoshihito Nagura, Kyoko Ito, Shintaro Ogawa, Hayato Kawamura, Kei Fujiwara, Katsuya Nagaoka, Etsuko Iio, Takehisa Watanabe, et al. MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. Journal of gastroenterology. 2024
Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Takayuki Tokunaga, Etsuko Iio, Takehisa Watanabe, Hiroko Setoyama, et al. Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology. 2024. 54. 5. 451-464
Takehisa Watanabe, Sanae Hayashi, Yan Zhaoyu, Hiroki Inada, Katsuya Nagaoka, Masakuni Tateyama, Yasuhito Tanaka. A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA. Journal of gastroenterology. 2024. 59. 4. 315-328
Xian-Yang Qin, Yohei Shirakami, Masao Honda, Shiou-Hwei Yeh, Kazushi Numata, Ya-Yun Lai, Chiao-Ling Li, Feifei Wei, Yali Xu, Kenji Imai, et al. Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence. International journal of cancer. 2024
Takanori Suzuki, Kentaro Matsuura, Yoshihito Nagura, Hayato Kawamura, Kei Fujiwara, Shintaro Ogawa, Katsuya Nagaoka, Etsuko Iio, Takehisa Watanabe, Hiromi Kataoka, et al. Serum angiopoietin-2 levels predict the development of hepatocellular carcinoma following hepatitis C virus eradication using direct-acting antiviral agents. Oncology. 2024
Katsuya Nagaoka, Yasuhito Tanaka, Okio Hino. The Tumor Microenvironment in Hepatocellular Carcinoma. Interdisciplinary Cancer Research. 2022
Katsuya Nagaoka, Chengcheng Ji, Xuewei Bai, Kevin Cao, Joud Mulla, Amalia Bay, William Mueller, Grace Hildebrand, Yasuhito Tanaka, Jack R. Wands, et al. ELEVATED 2-OXOGLUTARATE ANTAGONIZES CHEMOTHERAPEUTIC EFFECTS IN CHOLANGIOCARCINOMA BY TARGETING DNA DAMAGE RESPONSE SIGNALING PATHWAYS. HEPATOLOGY. 2021. 74. 687A-688A
Satoshi Narahara, Takehisa Watanabe, Kentaro Tanaka, Hiroki Inada, Sotaro Kurano, Takayuki Tokunaga, Yoko Yoshimaru, Katsuya Nagaoka, Hiroko Setoyama, Masakuni Tateyama, et al. NOVEL SERUM BIOMARKERS USEFUL FOR DRUG SELECTION OF SORAFENIB AND LENVATINIB FOR HEPATOCELLULAR CARCINOMA. HEPATOLOGY. 2021. 74. 658A-659A
Takayuki Tokunaga, Hiroki Inada, Kentaro Tanaka, Yoko Yoshimaru, Satoshi Narahara, Katsuya Nagaoka, Takehisa Watanabe, Masakuni Tateyama, Yasuhito Tanaka. OPTIMAL STRATEGY OF 1st OR LATER-LINE LENVATINIB THERAPY FOR PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA BY FOCUSING ON EARLY-PHASE RELATIVE DOSE INTENSITY. HEPATOLOGY. 2021. 74. 659A-659A